A single-center observational study investigating the utility of indocyanine green (ICG) fluorescence imaging in patients with benign bone tumors requiring intralesional operative management

Principal Investigator

Eric Henderson

Study Number

STUDY02000819

Summary

Patients with a biopsy-proven benign bone tumor for which standard of care is intralesional operative management will receive a weight-appropriate IV dose of indocyanine green (ICG, FDA-approved) the day prior to surgery during their standard pre-operative clinic visit. On the day of surgery, fluorescence images will be obtained using a non-invasive fluorescence camera.

Phase

N/A

Available at the following location(s)

• Lebanon

View more details at ClinicalTrials.gov

Do you need help with some of the labels on this page?
Read our glossary of terms